Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siriderma is a line of alkaline (slightly basic) dermocosmetic topical products developed by SIRIUS GmbH, a subsidiary of DR. KADE Pharma. These products are specifically formulated for individuals with dermatological conditions such as atopic dermatitis (neurodermatitis), psoriasis, and extremely dry or sensitive skin. The mechanism of action relies on an alkaline pH approach to soothe the skin, support the natural protective barrier, and promote regeneration. The formulations are vegan and free from alcohol, preservatives, and parabens, utilizing natural ingredients to provide lasting skin care. The product range includes specialized series such as Siriderma Med for problem skin, Siriderma Pure for active care, and Siriderma Care for gentle maintenance. The brand was acquired by DR. KADE Pharma in January 2019 and is manufactured in Germany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Siriderma.